Ketamine alcohol treatment is showing real promise for people struggling with alcohol use disorder. But a major new study has found something unexpected. The psychedelic “high” from ketamine plays no role in whether the treatment actually works.

New research from King’s College London and the University of Exeter was published in the journal Addiction. It challenges one of the most widely held assumptions in psychedelic-assisted therapy. The ketamine high, it turns out, is not the cure.

A Theory Put to the Test

For years, researchers believed the hallucinatory state induced by ketamine was behind its therapeutic value. People receiving ketamine infusions report vivid out-of-body sensations and altered perceptions of reality. It seemed reasonable to assume those experiences were doing the heavy lifting.

The new study draws on data from the Ketamine for Reduction of Alcoholic Relapse (KARE) clinical trial. It involved 96 adult participants across two clinical research facilities in England. This makes it the largest randomised controlled trial to date on intravenous ketamine-assisted psychotherapy for alcohol use disorder.

Participants received three weekly ketamine infusions. Researchers tracked both the intensity of psychoactive experiences and drinking behaviour over six months.

The result was clear. Participants reported strong hallucinatory effects across all three sessions. Yet the intensity of those experiences had no bearing on how many days they stayed alcohol-free. The ketamine alcohol treatment was working, but the high was not why.

What Ketamine Alcohol Treatment Research Actually Found

Dr Will Lawn, Senior Lecturer at King’s College London and study lead, said the findings open up new questions. “For the first time, we thoroughly investigated the acute psychoactive effects of repeated ketamine infusions in people with alcohol use disorder. The effects did not predict ketamine’s therapeutic benefit.”

One notable finding was that participants showed little tolerance to ketamine’s subjective effects across the short dosing schedule. The altered states remained just as intense in the third session as in the first. Yet even this consistency offered no clue as to who would stay sober.

Over 85,000 people in England receive treatment for alcohol use disorder each year. Many more go without. Professor Celia Morgan from the University of Exeter, who led the KARE trial, said there is a pressing need to diversify treatment options and improve long-term outcomes.

“Our research underscores that ketamine induces profound psychedelic effects in people with alcohol use disorder, but we still do not know the clinical reason why these experiences promote abstinence,” said Professor Morgan.

Where Does Ketamine Therapy for Alcohol Use Disorder Go Next?

The study does not undermine the case for ketamine as a treatment for problem drinking. Evidence from KARE and elsewhere has shown it can reduce relapse. What this research does is shift focus away from the subjective drug experience towards less visible mechanisms.

Ketamine acts on glutamate receptors in the brain. Researchers now believe the answer may lie in how the drug changes brain connectivity and function. Changes at the neural level may be doing more therapeutic work than the “high” itself.

This matters practically. Ketamine alcohol treatment could eventually be refined to retain its benefits while reducing the intensity of psychoactive effects. That could make it more accessible and easier to administer safely.

Research Emerging From the Next Generation

The lead author is Cassie Bloy, a BSc Psychology graduate from King’s College London. She began the analysis as her final year research project. Eighteen months later, it was published.

“Against our hypotheses, we did not find that ketamine’s well-known profound psychoactive effects predicted abstinence from alcohol,” she said.

A finding this significant emerging from an undergraduate project speaks to the strength of the KARE dataset. It also reflects growing investment in understanding how ketamine works at a deeper level.

A larger follow-up study is now under way across the UK. It is currently recruiting participants with alcohol problems. The focus will be on brain changes and optimising dosing to make ketamine alcohol treatment as effective as possible.

Why This Research Matters for Alcohol Recovery

Alcohol use disorder is one of the most common and hardest to treat conditions in the UK. Existing therapies help many people. But relapse rates remain high and many who need support never receive it.

The KARE trial represents a serious scientific effort to change that. Whether ketamine becomes a mainstream option for alcohol dependency will depend on studies like this one. Research that looks past the dramatic surface effects and asks harder questions about what is really going on.

Source: dbrecoveryresources